摘要
目的:探讨温肾强脊方联合美洛昔康治疗强直性脊柱炎(ankylosing spondylitis,AS)的临床疗效及对患者血清瘦素(leptin,LP)、白细胞介素-6(IL-6)、白细胞介素-17(IL-17)、白细胞介素-23(IL-23)的影响。方法:将80例强直性脊柱炎患者随机分为对照组(40例)与治疗组(40例),分别口服单药美洛昔康及温肾强脊方联合美洛昔康,疗程8周。观察治疗前后Bath强直性脊柱炎活动性指数(BASDAI)、Bath强直性脊柱炎功能指数(BASFI),检测外周血血沉(ESR)、C-反应蛋白(CRP)、LP、IL-6、IL-17、IL-23水平。结果:治疗后两组患者BASDAI、BASFI、ESR、CRP、LP、IL-6、IL-17、IL-23水平均比治疗前明显下降,治疗组BASDAI、BASFI、ESR、CRP、LP、IL-6、IL-17、IL-23均比对照组明显减低,无明显副作用。结论:温肾强脊方联合美洛昔康治疗强直性脊柱炎,对改善临床症状、降低ESR、CRP、LP、IL-6、IL-17、IL-23等方面均有显著疗效。
Objective： To evaluate the clinical efficacy of Wenshen Qiangji Decoction combined with meloxicam on Ankylosing Spondylitis（AS） and the effect on Leptin（LP）,IL-6,IL-17、IL-23. Methods： Eighty cases of patients with AS were randomly divided into the observation group and the control group（n = 40 in each group）. Patients in the observation group were treated with Wenshen Qiangji Decoction combined with meloxicam,and those in the control group only were treated with meloxicam. All were treated for eight weeks. BASDAI,BASFI,ESR,CRP,LP,IL-6,IL-17,IL-23 were examined in all patients. Results： After the treatment,levels of BASDAI,BASFI,ESR,CRP,LP,IL-6,IL-17,IL-23 in two groups were lower than those before the treatment（P〈0. 05）. Levels of BASDAI,BASFI,ESR,CRP,LP,IL-6,IL-17,IL-23 in the observation group were（4. 2 ± 1. 1,3. 0 ± 1. 1,21. 5 ± 7. 5,2. 59 ± 2. 2,4. 2 ± 0. 4,80. 4 ± 19. 6,10. 5 ± 2. 1,198. 9 ± 34. 2）,respectively,lower than those in the control group（5. 5 ± 1. 3,5. 6 ± 1. 3,33. 3 ± 7. 8,4. 7 ± 1. 6,6. 0 ± 0. 7,103. 2 ± 30. 9,18. 9 ± 4. 8,236. 6 ± 58. 7）（P〈0. 05）,and there were no obvious side effects. Conclusion： Wenshen Qiangji decoction combined with meloxicam in the treatment of AS can effectively improve clinical symptoms and reduce LP,IL-6,IL-17,IL-23 indicators.
作者
张征
许鸣华
常显
朱宁
秦烁
杨士鑫
魏凤菊
Zhang Zheng;Xu Minghua;Chang Xian;Zhu Ning;Qin Shuo;Yang Shixin;Wei Fengju(Affiliated Hospital of Hebei University, Baoding 071000;Baoding First Center Hospital, Departmentl of Cardiology, Baoding 071000;Zhongji Petrochemical Engineering Design Co. , Ltd, Baoding 071000)
出处
《中药药理与临床》
CAS
CSCD
北大核心
2018年第1期164-167,共4页
Pharmacology and Clinics of Chinese Materia Medica
基金
河北省保定市科学技术研究与发展指导计划资助项目(项目编号:17ZF271)
